Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients

Chemotherapy

Volumn 54, Issue 2, 2008, Pages 131-139

  Ikawa, Kazuro ^a   Morikawa, Norifumi ^a   Sakamoto, Kenichi ^a   Ikeda, Kayo ^a   Ohge, Hiroki ^a   Takesue, Yoshio ^a   Sueda, Taijiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Imipenem; Intraperitoneal fluid; Monte Carlo simulation; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CILASTATIN PLUS IMIPENEM; IMIPENEM;

ABDOMINAL INFECTION; ABDOMINAL SURGERY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTEROIDES FRAGILIS; CLINICAL ARTICLE; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG PERITONEAL FLUID LEVEL; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; ULCERATIVE COLITIS;

ADULT; AGED; ASCITIC FLUID; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; HUMANS; IMIPENEM; INFUSIONS, PARENTERAL; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

EID: 41349092138     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000118665     Document Type: Article

References (25)

1. Hellinger WC, Brewer NS: Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc 1999;74:420-434.
2. Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, Buchman T, Dellinger EP, Jernigan J, Gorbach S, Chow AW, Bartlett J: Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997-1005.
3. Tellado JM, Wilson SE: Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems. Surg Infect 2005;6:329-343.
4. Balfour JA, Bryson HM, Brogden RN: Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996;51:99-136.
5. Turnidge JD: The pharmacodynamics of beta-lactams. Clin Infect Dis 1998;27:10-22.
6. Craig WA: Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003;17:479-501.
7. Burmaster DE, Anderson PD: Principles of good practice for the use of Monte Carlo techniques in human health and ecological risk assessments. Risk Anal 1994;14:477-481.
8. Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA: Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001;45:13-22.
9. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL: Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005;55:601-607.
10. Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
11. Drusano GL: Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003;36(suppl 1):S42-S50.
12. Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
13. Garcia-Capdevila L, Lopez-Calull C, Arroyo C, Moral MA, Mangues MA, Bonal J: Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. J Chromatogr B Biomed Sci Appl 1997;692:127-132.
14. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T: A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 1981;4:879-885.
15. Shinagawa N, Hirata K, Katsuramaki T, Hata F, Ushijima Y, Ushida T, Tanimura H, Taniguchi K, Aikawa N, Yo K, Yamaue H, Ohnishi H, Takayama T, Sato T, Kato K, Tanaka N, Iwagaki H, Yura J, Fuchimoto S, Manabe T, Takeyama H, Kimura H, Hasegawa M, Takeuchi H, Yasui Y, Taniguchi M, Sueda T, Takesue Y, Mashita K, Hiyama E, Ishikawa S, Yokoyama T, Mizuno A, Ikeda S, Yasunami Y, Kubo S, Takada N, Suzuki Y, Fujimoto M: Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents - special references to bacteria isolated between April 2003 and March 2004. Jpn J Antibiot 2005;58:123-158.
16. Shinagawa N, Taniguchi M, Hirata K, Katsuramaki T, Mizukuchi T, Mashita K, Ushijima Y, Ushida T, Ishikawa S, Aikawa N, Yo K, Mizuno A, Takayama T, Sato T, Kato K, Kubo S, Suehiro S, Yura J, Fujimoto M, Manabe T, Takeyama H, Tanimura H, Taniguchi K, Hasegawa M, Yamaue H, Ohnishi H, Tanaka N, Iwagaki H, Kimura H, Tsumura H, Fuchimoto S, Yokoyama T, Sueda T, Takesue Y, Takeuchi H, Yasui Y, Hiyama E, Ikeda S, Yasunami Y: Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents - special references to bacteria isolated between April 2003 and March 2004. Jpn J Antibiot 2006;59:72-116.
17. Dreetz M, Hamacher J, Eller J, Borner K, Koeppe P, Schaberg T, Lode H: Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenemcilastatin. Antimicrob Agents Chemother 1996;40:105-109.
18. Peze P, Mounier M, Cevallos R, Denis F: Intraperitoneal penetration of imipenem/cilastatin during acute peritonitis. Pathol Biol 1990;38:504-507.
19. Benoni G, Arosio E, Raimondi MG, Pancera P, Lechi A, Velo GP: Pharmacokinetics of ceftazidime and ceftriaxone and their penetration into the ascitic fluid. J Antimicrob Chemother 1985;16:267-273.
20. Kuti JL, Florea NR, Nightingale CH, Nicolau DP: Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Pharmacotherapy 2004;24:8-15.
21. Moczygemba LR, Frei CR, Burgess DS: Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Clin Ther 2004;26:1800-1807.
22. Goldstein EJ, Snydman DR: Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 2004;53(suppl 2):ii29-ii36.
23. Rossi F, Baquero F, Hsueh PR, Paterson DL, Bochicchio GV, Snyder TA, Satishchandran V, McCarroll K, DiNubile MJ, Chow JW: In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006;58:205-210.
24. Buckley MM, Brogden RN, Barradell LB, Goa KL: Imipenem/cilastatin: a reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1992;44:408-444.
25. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL: Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002;50:425-428.